Biosimilars Market worth $1,954 Million by 2018
The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”, provides a detailed overview of the major drivers,restraints, challenges, opportunities, current market trends, and strategies impacting the global biosimilars market along with the estimates and forecasts of the revenue and share analysis.
Browse 80 market data tables and 80 figures spread through 320 pages and in-depth TOC on “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html Early buyers will receive 10% customization on reports.
The global biosimilars market is segmented on the basis of products, applications, and services. By product, the global biosimilars market is further segmented into recombinant non-glycosylated proteins (insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone), recombinant glycosylated proteins (erythropoietin, monoclonal antibodies, and follitropin), and recombinant peptides (glucagon and calcitonin). The recombinant glycosylated proteins segment is the largest segment and accounts for a share of 40% of the global biosimilars market in 2013at an estimated $314.2 million and is expected to grow at a CAGR of 17.5% from 2013 to 2018. The biggest factor behind the growth of this segment is the increasing demand for second-wave biosimilar products, such as insulin and interferon, for the treatment of diabetes and infectious disorders.Of all segments under the product category, the monoclonal antibodies segment is the fastest-growing segment at an estimated CAGR of more
Browse 80 market data tables and 80 figures spread through 320 pages and in-depth TOC on “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html Early buyers will receive 10% customization on reports.
The global biosimilars market is segmented on the basis of products, applications, and services. By product, the global biosimilars market is further segmented into recombinant non-glycosylated proteins (insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone), recombinant glycosylated proteins (erythropoietin, monoclonal antibodies, and follitropin), and recombinant peptides (glucagon and calcitonin). The recombinant glycosylated proteins segment is the largest segment and accounts for a share of 40% of the global biosimilars market in 2013at an estimated $314.2 million and is expected to grow at a CAGR of 17.5% from 2013 to 2018. The biggest factor behind the growth of this segment is the increasing demand for second-wave biosimilar products, such as insulin and interferon, for the treatment of diabetes and infectious disorders.Of all segments under the product category, the monoclonal antibodies segment is the fastest-growing segment at an estimated CAGR of more